Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
ciprofloxacin "hexal" 250 mg filmovertrukne tabletter
hexal a/s - ciprofloxacin - filmovertrukne tabletter - 250 mg
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiske midler - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiske midler - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
bavencio
merck europe b.v. - avelumab - neuroendocrine tumorer - andre antineoplastiske midler, monoklonale antistoffer - bavencio er indiceret som monoterapi til behandling af voksne patienter med metastatisk merkel cellecarcinom (mcc). bavencio i kombination med axitinib er angivet for den første linje behandling af voksne patienter med fremskredent renalcellecarcinom (rcc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
somatropin biopartners
biopartners gmbh - somatropin - vækst - pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists - somatropin biopartners er indiceret til erstatningsterapi af endogent væksthormon hos voksne med barndom- eller voksenbegyndende væksthormonmangel (ghd). voksen-debut: patienter med ghd i voksenalderen er defineret som patienter med kendt hypothalamus-hypofyse-patologi og mindst et yderligere kendt mangel af et hypofysehormon, undtagen prolaktin. disse patienter bør gennemgå en enkelt dynamiske test med henblik på at diagnosticere eller udelukke et ghd. barndom-debut: i patienter med barndommen-debut isoleret ghd (ingen tegn på hypothalamus-hypofyse-sygdom eller kraniel bestråling), to dynamiske tests bør udføres efter afslutningen af vækst, undtagen for dem, der har lave insulin-like-growth-faktor-i (igf-i) - koncentrationer (< -2 standard-afvigelse score (sds)), der kan anses for en test. cut-off point af den dynamiske test bør være strenge.
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
genotropin 12 mg pulver og solvens til injektionsvæske, opløsning
pfizer aps - somatropin, human biosyntetisk - pulver og solvens til injektionsvæske, opløsning - 12 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
genotropin 5 mg pulver og solvens til injektionsvæske, opløsning
pfizer aps - somatropin - pulver og solvens til injektionsvæske, opløsning - 5 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
genotropin miniquick 0,2 mg pulver og solvens til injektionsvæske, opløsning
pfizer aps - somatropin - pulver og solvens til injektionsvæske, opløsning - 0,2 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
genotropin miniquick 0,4 mg pulver og solvens til injektionsvæske, opløsning
pfizer aps - somatropin - pulver og solvens til injektionsvæske, opløsning - 0,4 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
genotropin miniquick 0,6 mg pulver og solvens til injektionsvæske, opløsning
pfizer aps - somatropin - pulver og solvens til injektionsvæske, opløsning - 0,6 mg